Jump to content

BPC-157

From Wikipedia, the free encyclopedia

BPC-157
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
DrugBank
UNII
  • InChI=1S/C62H98N16O22/c1-31(2)25-37(55(92)74-50(32(3)4)62(99)100)71-46(81)29-65-51(88)33(5)67-53(90)38(26-48(84)85)73-54(91)39(27-49(86)87)72-52(89)34(6)68-57(94)41-15-10-21-75(41)58(95)35(13-7-8-20-63)70-45(80)30-66-56(93)40-14-9-22-76(40)60(97)43-17-12-24-78(43)61(98)42-16-11-23-77(42)59(96)36(18-19-47(82)83)69-44(79)28-64/h31-43,50H,7-30,63-64H2,1-6H3,(H,65,88)(H,66,93)(H,67,90)(H,68,94)(H,69,79)(H,70,80)(H,71,81)(H,72,89)(H,73,91)(H,74,92)(H,82,83)(H,84,85)(H,86,87)(H,99,100)/t33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,50-/m0/s1
    Key: HEEWEZGQMLZMFE-RKGINYAYSA-N
  • C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@@H]3CCCN3C(=O)[C@@H]4CCCN4C(=O)[C@H](CCC(=O)O)NC(=O)CN
Properties
C62H98N16O22
Molar mass 1419.5 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N (what is checkY☒N ?)

Gastric Pentadecapeptide BPC-157 (also known as PL 14736, Body Protection Compound 157, or Bepecin) is a fifteen amino acid long oligopeptide that was discovered during research on human gastric juice.[1] The amino acid sequence is as follows: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.[2]

BPC-157 is stable at room temperature and is resistant to hydrolysis, enzyme digestion, and gastric juice.[3]

Research

[edit]

Pre-clinical research has indicated that BPC-157 may have cytoprotective, neuroprotective, and anti-inflammatory effects, and may also accelerate tissue and organ healing.[4][5][6][7] [8][9]

This substance is sometimes used in functional medicine despite not being approved by any drug regulatory agency.[10]

As of 2022, the peptide is banned by the World Anti-Doping Agency under the S0 category of non-exempt substances.[11]

References

[edit]
  1. ^ Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH (2011). "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration". Journal of Applied Physiology. 110 (3). American Physiological Society: 774–780. doi:10.1152/japplphysiol.00945.2010. ISSN 8750-7587.
  2. ^ Jelovac N, Sikiric P, Rucman R, Petek M, Marovic A, Perovic D, et al. (August 1999). "Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats". European Journal of Pharmacology. 379 (1): 19–31. doi:10.1016/S0014-2999(99)00486-0. PMID 10499368.
  3. ^ He L, Feng D, Guo H, Zhou Y, Li Z, Zhang K, et al. (2022-12-14). "Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs". Frontiers in Pharmacology. 13. Frontiers Media SA. doi:10.3389/fphar.2022.1026182. ISSN 1663-9812. PMC 9794587. PMID 36588717.
  4. ^ Vukojevic J, Milavić M, Perović D, Ilić S, Čilić AZ, Đuran N, et al. (March 2022). "Pentadecapeptide BPC 157 and the central nervous system". Neural Regeneration Research. 17 (3): 482–487. doi:10.4103/1673-5374.320969. PMC 8504390. PMID 34380875.
  5. ^ Chang C, Tsai W, Lin M, Hsu Y, Pang JS (October 28, 2010). "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration". Journal of Applied Physiology. 110 (3): 774–780. doi:10.1152/japplphysiol.00945.2010. PMID 21030672.
  6. ^ Staresinic M, Sebecic B, Patrlj L, Jadrijevic S, Suknaic S, Perovic D, et al. (2003). "Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth". Journal of Orthopaedic Research. 21 (6): 976–983. doi:10.1016/S0736-0266(03)00110-4. PMID 14554208.
  7. ^ Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, et al. (2011). "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract". Current Pharmaceutical Design. 17 (16): 1612–32. doi:10.2174/138161211796196954. PMID 21548867.
  8. ^ Sikiric P, Seiwerth S, Brcic L, Blagaic AB, Zoricic I, Sever M, et al. (December 2006). "Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response". Inflammopharmacology. 14 (5–6): 214–221. doi:10.1007/s10787-006-1531-7. PMID 17186181. S2CID 24132425.
  9. ^ Cerovecki T, Bojanic I, Brcic L, Radic B, Vukoja I, Seiwerth S, et al. (September 2010). "Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat". Journal of Orthopaedic Research. 28 (9): 1155–1161. doi:10.1002/jor.21107. PMID 20225319. S2CID 22085833.
  10. ^ Sikiric P, Seiwerth S, Rucman R, Kolenc D, Vuletic LB, Drmic D, et al. (2016). "Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications". Current Neuropharmacology. 14 (8): 857–865. doi:10.2174/1570159x13666160502153022. PMC 5333585. PMID 27138887.
  11. ^ "2022 Prohibited List: SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)" (PDF). World Anti-Doping Agency. WADA. Retrieved 21 February 2022.
Retrieved from "https://wiki.riteme.site/w/index.php?title=BPC-157&oldid=1259758518"